BornemannR., SmithM.D., GerlachJ.C.Consideration of potential immunogical problems in the application of xenogenic hybrid liver support.Int J Artif Organs1996; 19: 655–63.
2.
TakahashiM., IshikuraH., TakahashiC.. Immunologic considerations in the use of cultured porcine hepatocytes as a hybrid artificial liver. Anti-porcine hepatocyte human serum.ASAIO J1992; 39: M242–6.
3.
OriolR., YeY., KorenE., CooperD.K.C.. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-toman organ transplantation.Transplantation1993; 56: 1433–1442.
4.
SykesM.. Immunobiology of transplantation.FASEB J1996; 10: 721–30.
NybergS.L., PlattJ.L., ShirabeK., PayneW.D., HuW-S, CerraF.B.. Immunoprotection of xenocytes in a hollow fiber bioartificial liver.ASAIO Journal1992; 38: M463–7.
7.
FlendrigL.M., La SoeJ.W., JörningG.A.. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates.J Hepatol1997 (in press).
8.
DixonF.J., VasquezJ.J., WeigleW.O., CochraneC.G.. Pathogenesis of serum sickness.AMA Arch of Pathol1958; 65: 18–28.
9.
LanzaR.P., BeyerA.M., ChickW.L.. Xenogeneic humoral responses to islets transplanted in biohybrid diffusion chambers.Transplantation1994; 57: 1371–5.
10.
AbounaG.M., AmemiyaH., AndresG., PorterK.A., HamiltonD.. Immunological studies in patients receiving repeated allogeneic and xenogeneic liver hemoperfusions.Transplantation1974; 18: 395–408.
11.
Te VeldeA.A., FlendrigL.M., LadigesNCJJ, ChamuleauRAFM. Immunological consequences of the use of xenogeneic hepatocytes in a bioartificial liver for acute liver failure.Int J Artif Organs.1997; 20: 229–33.
12.
ThomasH.C.. The role of the liver in immunological disease.Proc Roy Soc Med1977; 70: 521–5.
13.
ChaseM.W.. Inhibition of experimental drug allergy by prior feeding of the sensitizing agent.Proc Soc Biol Med1946; 62: 257–9.
14.
TrigerD.R.. Bacterial, viral and autoantibodies in acute and chronic liver disease.Ann Clin Res1976; 8: 174–81.
15.
LindgrenS., ErikssonS.. IgM in primary biliary cirrhosis: physicochemical and complement activating properties.J Lab Clin Med1982; 99: 636–45.
16.
LedermanS., YellinM.J., ClearyM.L.. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues from programmed cell death.J Immunol1994; 152: 2163–2171.
17.
CanaleseJ., GoveC.D., GimsonA.E.S., WilkinsonS.P., WardleZ.N., WilliamsR.. Reticuloendothelial system and hepatocyte function in fulminant hepatic failure.Gut1982; 23: 265–9.
18.
ImawariM., HughesR.D., GoveC.D., WilliamsR.. Fibronectin and Kupffer cell function in fulminant hepatic failure.Dig Dis Sci1985; 30: 1028–33.
19.
BenacerrafB., SebestyenM.M.. Effects of bacterial endotoxins on the reticuloendothelial system.Fed Proc1957; 16: 860–7.
20.
TheofilopoulosA.N., DixonF.J.. The biology and detection of immune complexes.Adv Immunol1979; 28: 89–220.
21.
KosmidisJ.C., Leader-WilliamsL.K.. Complement levels in acute infection hepatitis and serum hepatitis.Clin Exp Immunol1972; 11: 31–5.
22.
MacDonaldT.T.. Eating your way towards immunosuppression.Current Biology1994; 4: 178–81.
HewittW.R., RozgaJ., ChenS.C., WatanabeF., KahakuE., MiddletonY., ArnaoutW., SchackletonC., DemetriouA.A.. Treatment of fulminant hepatic failure (FHF) with a bioartificial liver (BAL).Int J Artif Organs1996; 19: 548.
25.
RozgaJ., PodestaL., LePageE.. A bioartificial liver to treat severe acute liver failure.Ann Surg1994; 219: 538–46.
26.
RozgaJ., PodestaL., HoffmanA.. Control of celebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure.Lancet1993; 342: 898–9.
